Polydatin alleviates adenine-induced nephropathy in mice Authors: Tao Sheng, Tianhong Ma, Xin Jin, Debin Chen, Shipeng Che, Jie Wang, Jiadu Shen, Chaoqun Shi, Qiang Li, Yixin Sun, Deqing Chen, Guangtao Xu Published: 2026 ABSTRACT AbstractBackgroundAdenine-induced nephropathy (AIN) serves as a classic experimental model for studying uric acid-related renal injury, characterized by tubular obstruction, inflammatory cell infiltration, tubular epithelial cell apoptosis, and progressive interstitial fibrosis, among others. These pathological changes are primarily driven by intrarenal deposition of adenine metabolites, and the model reliably recapitulates both hyperuricemia and impaired renal function. The aim of this study was to assess the renoprotective potential of polydatin (PD) in a murine model of AIN.MethodsFifty male mice (weight, 20 ± 2 g) obtained from The Institute of Cancer Research were randomly assigned into five groups (n = 10 each): normal, AIN model, PD treatment, allopurinol treatment, and desuric benzbromarone (DB) treatment. Changes in oxidative stress, inflammatory response, apoptosis, fibrosis, renal function, and pathological morphology of renal tissue were investigated in mice with AIN.ResultsThe outcomes of the present study revealed that renal function and renal histopathology in mice were significantly abnormal in the AIN group. After treatment with PD, it was observed that these abnormal indices were significantly improved, and the structure and function of renal histopathology were significantly protected.ConclusionsPD exhibited a significant therapeutic effect in mice with AIN, which may play a role in protecting the kidneys by regulating various biological processes such as immune inflammation, apoptosis, and fibrosis, providing an important experimental basis and theoretical basis for the clinical use of PD in treating AIN. Introduction Adenine-induced nephropathy (AIN) is characterized by hyperuricemia, which results from excessive adenine administration and metabolic disturbance, leading to tubular injury, inflammation, interstitial fibrosis, and progressive renal dysfunction [1–3]. Urate homeostasis is tightly regulated by multiple organ systems, with the kidneys responsible for eliminating more than 70% of endogenous uric acid, thereby positioning them as the primary site of uric acid-mediated damage [4,5]. This homeostatic equilibrium is maintained by a coordinated network of renal urate transporters, including urate transporter 1 (URAT1) and ATP-binding cassette subfamily G member 2 (ABCG2), which govern urate reabsorption and secretion [6]. Dysregulation of these transporters represents a key pathophysiological mechanism underlying both hyperuricemia and the progression of AIN [4,7]. Experimental and epidemiological studies have demonstrated that hyperuricemia is growing increasingly prevalent worldwide [8,9] and that hyperuricemia-associated renal injury, such as uric acid nephropathy (UAN), is also rising in incidence [10]. Compared to individuals with isolated hyperuricemia, those with UAN complicated by gout face a significantly elevated risk of progressing to end-stage renal disease (ESRD) [11,12]. Histopathological examinations reveal that AIN is characterized by tubular injury, tubulointerstitial inflammation and fibrosis, accompanied by intratubular deposition of crystals and hyperuricemia [13,14]. Persistent hyperuricemia often leads to gout, a condition resulting from the accumulation of monosodium urate (MSU) crystals in joints and surrounding soft tissues [11,15,16]. Gout is closely associated with AIN and chronic kidney disease (CKD). MSU crystals can directly deposit in renal tissue, leading to crystal-induced nephropathy, and can also trigger systemic inflammation via activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, thereby aggravating renal fibrosis [4,11,17]. Without timely and appropriate diagnosis and treatment, AIN may accelerate the progression to ESRD [13]. At present, the primary pharmacological approaches for managing hyperuricemia mainly consist of xanthine oxidase inhibitors, including allopurinol and febuxostat, along with uricosuric drugs such as desuric benzbromarone (DB) and lesinurad [18]. While these therapies effectively reduce serum uric acid (SUA) levels, recent comparative studies have revealed several critical limitations: (1) Allopurinol and febuxostat are associated with hepatotoxicity and increased cardiovascular risks, particularly in patients with CKD [19–21]; (2) DB is contraindicated in individuals with moderate-to-severe renal impairment due to a heightened risk of uric acid stone formation[18,22]; (3) Most single-target agents do not adequately address the multifaceted pathological cascade of AIN, such as concurrent inflammation, oxidative stress, and fibrosis [23]. Obviously, their utility is constrained by notable adverse effects and a single-target mechanism that does not adequately address the multifaceted pathological cascade of AIN, which encompasses inflammation, oxidative stress, and fibrosis. Consequently, there is an urgent clinical demand for safer, multitarget therapeutic agents capable of not only lowering uric acid but also directly mitigating renal injury through anti-inflammatory, antioxidant, and antifibrotic actions. Polygonum cuspidatum is a traditional herbal medicine widely utilized in East Asia, including China, Japan, and Korea [24,25]. Polydatin (PD), a principal bioactive compound isolated from P. cuspidatum, has attracted considerable research interest owing to its potential renoprotective effects [26,27], which are primarily attributed to its antioxidant (e.g., scavenging reactive oxygen species and activating the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 (Nrf2/HO-1) pathway), anti-inflammatory (e.g., inhibition of nuclear factor kappa-B (NF-κB) signaling), and antifibrotic properties (e.g., modulation of the transforming growth factor-β/Smad (TGF-β/Smad) pathway) [28–31]. Unlike conventional single-target therapeutics, PD demonstrates multi-pharmacological properties that are well aligned with the complex pathophysiology of AIN. Nevertheless, despite extensive research in various other disease models, investigations into its therapeutic potential for AIN remain limited [32]. The present study aimed to investigate the mechanisms underlying the protective effects of PD against AIN in a murine model, elucidate the underlying pharmacological mechanisms, and provide theoretical support for the development of novel therapeutic strategies for uric acid-related renal injury. Ultimately, this work will enhance our understanding of AIN pathogenesis and contribute to the exploration of innovative approaches for its treatment. Materials and methods Compliance with ethical standards All laboratory protocols and the treatment of the mice used in this research received approval from the Ethics Committee of Jiaxing University Medical College (Jiaxing, China; Approval No. JUMC2024-096). All animal experiments were performed in strict compliance with the Guide for the Care and Use of Laboratory Animals issued by the National Institutes of Health (NIH), ensuring ethical treatment and minimizing distress throughout the study. Mice were euthanized via intraperitoneal administration of sodium pentobarbital (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany; Cat. No.: P3761) at a dosage of 50 mg/kg to induce deep anesthesia. The success of euthanasia was verified by the cessation of heartbeat and respiration, pupil dilation, and loss of limb reflexes, to ensure a humane and painless process. In line with the approved ethical guidelines and fundamental principles of animal welfare, established humane endpoints were applied to reduce unnecessary suffering in mice. These endpoints aligned with recognized criteria for AIN models [33,34]. Mice meeting any of the following criteria were humanely euthanized immediately using the method described above: (1) severe body weight loss (>20% of baseline weight within 7 days); (2) persistent lethargy, inability to stand, or failure to access food or water independently; (3) clinical signs of advanced renal failure, including oliguria, hematuria, or abdominal distension; (4) markedly abnormal physiological parameters as confirmed by urgent blood biochemical analysis, specifically, serum creatinine (Scr) >300 μmol/L or blood urea nitrogen (BUN) >25 mmol/L. Mouse model establishment A total of 60 male mice (weight, 20 ± 2 g) obtained from the Institute of Cancer Research (ICR) were supplied by the Laboratory Animal Center of the Medical College of Jiaxing University (Jiaxing, China). Of these, 50 mice were initially enrolled in the experiment; an additional 10 mice served as replacements for those that died prior to the experimental endpoint. Before the experiment commenced, all mice underwent one-week acclimatization period under standardized environmental conditions, including a 12-h light/dark cycle, a temperature range of 22 °C to 24 °C, and 50% to 60% humidity, with unrestricted access to standard chow and tap water. The initial cohort of 50 mice was randomly assigned to five groups as follows: (i) Normal (n = 10; standard feeding, no treatment and unrestricted availability of food and water); (ii) AIN group (n = 10); (iii) PD treatment group (n = 10; 15 mg/100g PD intragastrically administered after successful AIN model induction); (iv) allopurinol treatment group (n = 10; 1 mg/100g allopurinol intragastrically administered after successful AIN model induction); and (v) DB treatment group (n = 10; 1 mg/100g DB intragastrically administered after successful AIN model induction). In groups ii–v, yeast powder (Kangzhuang Bio-Fermentation Products Co., Ltd., Cangzhou, China; Cat. No.: KZ-Y-002) feed was combined with a 0.1% solution of adenine (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany; Cat. No.: A8626) mixed in normal saline and was administered intragastrically, three times daily [35,36]. After 5 weeks, urine samples were collected over a 24 h period to evaluate the levels of uric acid. If uric acid content was >200 μmol/l, renal injury was considered successful. Groups iii–v received PD (Shanghai Macklin Biochemical Technology Co., Ltd., Shanghai, China; Cat. No.: P819423), allopurinol (Shanghai Macklin Biochemical Technology Co., Ltd., Shanghai, China; Cat. No.: A800424) and DB (Shanghai Macklin Biochemical Technology Co., Ltd., Shanghai, China; Cat. No.: B794095) for 4 weeks after successful induction of the renal injury model, respectively. During the 4 week AIN model induction period and subsequent drug intervention phase, varying degrees of mouse death occurred in each group. The specific mortality rate and animal replacement status were as follows: (i) Normal, 0% mortality (no death); (ii) AIN group, 30% mortality (3 out of 10 mice died); (iii) PD treatment group, 20% mortality (2 out of 10 mice died); (iv) allopurinol treatment group, 20% mortality (2 out of 10 mice died); (v) DB treatment group, 30% mortality (3 out of 10 mice died). All deceased mice were replaced with strict adherence to standardized protocols. Replacement mice were carefully selected to match the deceased individuals in age, body weight, and baseline physiological parameters and were assigned to their original experimental groups according to the initial randomization scheme. Except for the normal group, all replacement mice underwent identical AIN model induction and drug intervention procedures prior to re-entry into the study. Ultimately, the final sample size in each group was restored to n = 10, thereby preserving intergroup comparability and ensuring adequate statistical power for downstream analyses. Mice were ultimately euthanized under deep anesthesia induced by an intraperitoneal injection of pentobarbital sodium at a dose of 50 mg/kg. Blood samples, approximately 0.2 mL each, were obtained through abdominal aortic puncture and subsequently centrifuged at 4 °C and 3,500 rpm for 15 min using a Centrifuge 5804 R (Eppendorf SE) to separate the serum. Kidney tissues were collected from all mice; one half was preserved in 4% neutral-buffered paraformaldehyde diluted in phosphate-buffered saline for later histopathological examination, while the other half was rapidly frozen and stored at −80 °C for subsequent molecular analyses. Biochemical determination To comprehensively assess renal function, uric acid metabolism, and oxidative damage in renal tissue of mice, a series of biochemical assays were performed. Renal function was assessed through the measurement of urinary microalbuminuria (mAlb), along with serum levels of blood urea nitrogen (BUN) and creatinine (Scr). Urinary mAlb levels were quantified with the Mouse Microalbuminuria (MAU) ELISA Kit (Sangon Biotech Co., Ltd., Shanghai, China; Cat. No.: D721120). Serum BUN and Scr concentrations were measured on a Hitachi 7600 Clinical Automatic Biochemistry Analyzer (Hitachi, Ltd.) with assay kits supplied by Roche Diagnostics GmbH. Urinary mAlb concentration was expressed as mg/24 h, BUN concentration was expressed as mmol/l, and Scr concentration was expressed as μmol/l. The determination of uric acid content holds significant clinical diagnostic value as levels of SUA and urine uric acid (UUA) reflect the content of uric acid in mice. SUA and UUA were measured using the Uric Acid (UA) Content Assay Kit (Sangon Biotech Co., Ltd.; micromethod). Furthermore, the ratios of SUA/mAlb and UUA/mAlb were calculated by dividing the respective SUA or UUA concentration by the corresponding urinary mAlb value (SUA/mAlb or UUA/mAlb). SUA and UUA were expressed as μmol/l. The concentrations of lactate dehydrogenase (LDH) and superoxide dismutase (SOD) in the mice renal tissue reflected whether the kidneys had undergone damage caused by peroxidation reactions. LDH and SOD were measured with the Lactate Dehydrogenase (L-LDH) Activity Assay Kit (Sangon Biotech Co., Ltd., Shanghai, China; Cat. No.: D799208) and the Superoxide Dismutase (SOD) Activity Assay Kit (Sangon Biotech Co., Ltd., Shanghai, China; Cat. No.: D799594), respectively. The level of LDH was quantified as U/ml, with SOD activity quantified as U/mg protein. Assessment of renal injury After being preserved in 4% neutral paraformaldehyde in PBS for 48 h, the renal tissue was embedded in paraffin and serially cut into 4-µm-thick slices. Staining was performed using staining protocols for hematoxylin–eosin (HE) staining with instructions procedures, using the ST lnfinity H&E Staining System (Leica GmbH, Wetzlar, Germany; Cat. No.: 3801698). To assess the extent of fibrosis, Masson’s trichrome staining was carried out using a commercial kit (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China; Cat. No.: G1340). Histopathological changes were observed using a microscope and imaging system (DM3000 LED; Leica Microsystems GmbH), and scored based on the damage degree, which was determined by the percentage of affected renal tissue. Histological sections were assessed in a blind manner by two independent pathologists. Renal tissue damage was assessed based on a grading system that considered tubular cell necrosis, apoptosis, cytoplasmic vacuolation, hemorrhage, and tubular dilatation. Scores were assigned to 10 corresponding regions per sample. Higher scores represent a greater severity of damage in a five-score system [37]: (i) 0, microlesion (0–10%); (ii) 1, small lesion (11–25%); (iii) 2, mild injury (26–50%); (iv) 3, moderate injury (51–75%); and (v) 4, severe injury (75–100%). For each parameter, the mean score was calculated and then analyzed statistically. Immunohistochemistry Renal tissue samples were fixed in paraffin and cut into serial sections of 5 μm thickness. These sections were subsequently subjected to immunohistochemical staining via the streptavidin–peroxidase technique. To block nonspecific binding sites, the tissue sections were first deparaffinized, rehydrated, and washed, then treated with 3% hydrogen peroxide. The sections were incubated with the following rabbit anti-mouse primary antibodies: Interleukin 4 (IL-4; 1:400; CLOUD-CLONE CORP (CCC), Houston, USA; Cat. No.: PAA077Mu02), tumor necrosis factor α (TNF-α; 1:200; CLOUD-CLONE CORP (CCC), Houston, USA; Cat. No.: PAA133Mu02), B-cell CLL/lymphoma 2 (Bcl-2; 1:400; CLOUD-CLONE CORP (CCC), Houston, USA; Cat. No.: PAA778Mu02), caspase 3 (CASP3, 1:200; CLOUD-CLONE CORP (CCC), Houston, USA; Cat. No.: PAA626Mu01) and transforming growth factor β1 (TGF-β1, 1:200; CLOUD-CLONE CORP (CCC), Houston, USA; Cat. No.: PAA124Mu02) at 4 °C overnight. The corresponding secondary antibody (1:400; goat anti-rabbit IgG; Zymed; Thermo Fisher Scientific, Inc., Waltham, MA, USA; Cat. No.: 31460) was incubated as per the manufacturer’s instructions, followed by counterstaining with hematoxylin. The images were observed under a microscope and imaging system (DM3000 LED; Leica Microsystems GmbH). The integral optical density (OD) of immunohistochemical staining was quantified using Leica Application Suite V4.13 (Leica Microsystems GmbH). For negative controls, selected sections were processed either with rabbit tissue or PBS in the absence of primary antibodies. Under these conditions, no false-positive or false-negative staining was observed. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) To assess IL-4, TNF-α, Bcl-2, CASP3, and TGF-β1 mRNA expression, total RNA was isolated from renal tissues using RNAiso Plus (Takara Bio, Inc., Kusatsu-shi, Shizuoka-ken, Japan; Cat. No.: 9108), following the manufacturer’s instructions. The OD for every RNA sample was quantified using the Tecan 200 Pro (Tecan Group, Ltd.) microplate reader with a NanoQuant Plate™. Complementary DNA (cDNA) was generated from 1 µg of total RNA by reverse transcription using the M5 Super qPCR RT kit (Mei5 Biotechnology Co., Ltd., Beijing, China; Cat. No.: MF166). The resulting cDNA was used for RT-qPCR, in which glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was employed as the internal control and RNase free H2O as the negative control. The primer sequences used in this research are presented in Table 1. Using QuantStudio 3 (Thermo Fisher Scientific, Inc.), RT-qPCR was carried out in a 20 μl reaction mixture comprising 2X PCR Super mix (Thermo Fisher Scientific, Inc., Waltham, MA, USA; Cat. No.: 11762500), primers, cDNA, and RNase-free H2O. PCR was run under the following cycling conditions: 2 min at 95 °C; 15s at 95 °C, 30s at 60 °C and 45s at 72 °C for 40 cycles; and 5 min at 72 °C. The RT-qPCR procedure was carried out in triplicate for each sample. The mRNA relative expression was calculated using the 2ΔΔCq method. Table 1.Primers sequences in real-time polymerase chain reaction.GeneForward primer (5′-3′)Reverse primer (5′-3′)Product length (bp)IL4AAGGAACACCACGGAGAACGAGACCGCTGACACCTCTACA147TNF-αTCGTCTACTCCTCAGAGCCCACTTCAGCGTCTCGTGTGTT128Bcl-2CCTGGCTGTCTCTGAAGACGGCATATTTGTTTGGGGCAGGTC113CASP3GAGCTTGGAACGCGAAGAAATTGCGAGCTGACATTCCAGT221TGF-β1GAGAGCCCTGGATACCAACTACTGCCAACCCAGGTCCTTCCTAAAGTCAA93GAPDHTATGTCGTGGAGTCTACTGGTGAGTTGTCATATTTCTCGTGG149Note. IL-4: interleukin 4; TNF-α: tumor necrosis factor α; Bcl-2: B-cell CLL/lymphoma 2; CASP3: caspase 3; TGF-β1: transforming growth factor β1; GAPDH: glyceraldehyde-3-phosphate dehydrogenase. Primers sequences in real-time polymerase chain reaction. Note. IL-4: interleukin 4; TNF-α: tumor necrosis factor α; Bcl-2: B-cell CLL/lymphoma 2; CASP3: caspase 3; TGF-β1: transforming growth factor β1; GAPDH: glyceraldehyde-3-phosphate dehydrogenase. Statistical analysis For the recording and analysis of all data, a Microsoft Excel 2010 and SPSS Statistics 23.0 software (IBM Corp.) were utilized. All experimental measurements, including biochemical indices and morphological and molecular assessments, were carried out with three independent replicates. Data are presented as the mean ± standard deviation. For comparisons involving multiple groups, statistical evaluation was conducted using one-way ANOVA. Where significant differences were detected, the Newman–Keuls multiple comparison test was applied. The threshold for statistical significance was established at p < 0.05. Results PD improves renal dysfunction after renal injury The impact of PD on renal function in AIN was evaluated by examining several key biomarkers, including urinary mAlb, BUN, and Scr. Relative to the normal group, levels of all three parameters were significantly elevated in the AIN group, as well as in the PD-treated, allopurinol-treated, and DB-treated groups (p < 0.05; Figure 1), confirming successful induction of renal injury by adenine. Notably, all three treatment groups exhibited statistically significant reductions in these renal function markers compared with the untreated AIN group (p < 0.05; Figure 1). Collectively, these findings indicate that PD ameliorates AIN, thereby providing a mechanistic basis for subsequent investigations into its regulatory effects on uric acid metabolism and associated pathological pathways. The renal function analyses. The concentrations of (A) microalbuminuria, (B) serum BUN, and (C) Scr were significantly increased both in AIN group, PD treatment group, allopurinol treatment group and DB treatment group, however, the treatment group of PD, allopurinol and DB showed markedly lower levels compared with the AIN group. The data are presented as means ± standard deviation (SD). *p < 0.05 vs. normal group, # p < 0.05 vs. AIN group. BUN: serum blood urea nitrogen; Scr: serum creatinine concentration; AIN: adenine-induced nephropathy; PD: polydatin; DB: desuric benzbromarone. PD can reduce the accumulation of uric acid and modulate the SUA/mAlb and UUA/mAlb ratios in the body Given that uric acid accumulation is a key trigger of AIN, we further measured SUA and UUA concentrations to elucidate the regulatory effect of PD on uric acid metabolism. Prior to drug administration, baseline SUA and UUA levels were comparable across the AIN group and the three treatment groups (all p > 0.05), and all were significantly elevated relative to those in the normal group, thereby confirming successful establishment of the AIN model characterized by uric acid accumulation before intervention. After drug intervention, the AIN group still showed significantly increased SUA and UUA concentrations compared with the normal group (p < 0.05; Figure 2). However, a downregulation was observed in the PD-treated group, allopurinol-treated group, and DB-treated group (p < 0.05; Figure 2). These findings suggest that PD effectively attenuates uric acid accumulation in vivo. The levels of (A) SUA and (B) UUA. Compared with the normal groups, the concentrations of SUA and UUA were significantly increased in the AIN group, there was down-regulation in PD treated group, allopurinol treatment group and DB treated group. The data are presented as means ± standard deviation (SD). *p < 0.05 vs. normal group, #p < 0.05 vs. AIN group. SUA: serum uric acid; UUA: urine uric acid; AIN: adenine-induced nephropathy; PD: polydatin; DB: desuric benzbromarone. To further investigate the comprehensive impact of PD on the renal microenvironment, we evaluated the SUA/mAlb and UUA/mAlb ratios (Table 2). These composite biomarkers offer greater sensitivity and clinical relevance than uric acid levels alone, as they jointly reflect the pro-inflammatory effects of hyperuricemia and the systemic inflammatory status and endothelial dysfunction indicated by microalbuminuria. Table 2 shows that PD significantly reduced both UUA/mAlb and SUA/mAlb ratios, indicating its capacity to modulate AIN-associated inflammatory injury and preserve renal homeostasis. This moderate restoration of the ratios is clinically advantageous in CKD, as it avoids imposing additional stress on the kidneys. In contrast, allopurinol more effectively reduced UUA/mAlb via urate reduction but modestly improved SUA/mAlb due to limited structural protection. DB exhibited slightly less efficacy, potentially attributable to impaired renal tubular function in the setting of established kidney injury. These findings collectively demonstrate the greater efficacy of PD, and allopurinol compared to uricosuric drugs for managing CKD. Collectively, these findings indicate that PD and allopurinol confer greater therapeutic benefits than uricosuric agents in patients with CKD, providing a rationale for further investigation into the renoprotective mechanisms of PD. Table 2.The SUA/mAlb and UUA/mAlb ratios in each group.Group (n = 10)SUA/mAlbUUA/mAlbNormal10.3635.02AIN2.185.62AIN + PD2.446.04AIN + allopurinol2.406.36AIN + DB2.225.83Note. SUA: serum uric acid; UUA: urine uric acid; mAlb: microalbuminuria; AIN: adenine-induced nephropathy; PD: polydatin; DB: desuric benzbromarone. The SUA/mAlb and UUA/mAlb ratios in each group. Note. SUA: serum uric acid; UUA: urine uric acid; mAlb: microalbuminuria; AIN: adenine-induced nephropathy; PD: polydatin; DB: desuric benzbromarone. PD decreases the oxidative stress after renal injury We observed a significant elevation in LDH activity and a concurrent reduction in SOD activity in the AIN group relative to the normal group (p < 0.05; Figure 3), indicative of heightened oxidative stress and compromised antioxidant defense in renal tissue – hallmark pathological features of AIN. The PD-treated group demonstrated increased SOD activity and reduced LDH activity in comparison with the AIN group (p < 0.05; Figure 3). By attenuating adenine-induced oxidative stress, PD appears to restore the antioxidant function of renal tissue, as supported by these results. The renal oxidative stress parameter (A) LDH and (B) SOD analyses. Compared with the normal groups, the LDH activity was significantly elevated in AIN group, while SOD activity was significantly decreased. PD treated group, allopurinol treatment group and DB treated group increased SOD activity and reduced LDH activity in comparison to AIN group. The data are presented as means ± standard deviation (SD). *p < 0.05 vs. normal group, #p < 0.05 vs. AIN group. LDH: lactate dehydrogenase; SOD: superoxide dismutase; AIN: adenine-induced nephropathy; PD: polydatin; DB: desuric benzbromarone. PD alleviates pathological damage after renal injury The analysis of the routinely HE-stained renal tissue sections revealed varying degrees of renal pathological damage in the AIN groups. In AIN, the renal tubules are most significantly affected, including cellular edema, tubular dilatation and protein accumulation in the lumen (Figure 4). These abnormalities indicated that AIN was successfully established. In the normal group, histological analysis confirmed the absence of any pathological lesions in both glomerular and tubular structures. The AIN group exhibited a significantly higher renal damage score compared with the normal group. (p < 0.05; Figure 5). In the PD, allopurinol and DB treatment groups, renal tissue damage was reduced to different degrees and the expansion of renal tubules, and cellular edema and interstitial congestion were improved (p < 0.05; Figure 5). These results demonstrate that PD attenuated the unfavorable renal pathological process. The routine HE-stains of renal tissue (original magnification, 200×). The renal cortex of normal group (A), AIN group (C), PD treatment group (E), allopurinol treatment group (G), and DB treatment group(I); and the renal medulla of normal group (B), AIN group (D), PD treatment group (F), allopurinol treatment group (H) and DB treatment group (J). In the renal cortex, different degrees of renal tubular edema can be seen (C, E, G, I). In the medulla, swelling and dilation of renal tubules congestion of renal interstitium and protein deposition in the tubules can be observed (B, D, F, J). AIN: adenine-induced nephropathy; PD: polydatin; DB: desuric benzbromarone. The analysis of the renal damaged score. The data are presented as means ± standard deviation (SD). *p < 0.05 vs. normal group, #p < 0.05 vs. AIN group. AIN: adenine-induced nephropathy; PD: polydatin; DB: desuric benzbromarone. PD alleviates inflammatory activity after renal injury To better understand the anti-inflammatory properties of PD in AIN, the expression levels of key inflammatory cytokines in kidney tissues were assessed by immunohistochemistry (Figures 6 and 7) and RT-qPCR (Figure 8). Compared with the normal group, the AIN group, as well as in the PD-, allopurinol- and DB-treated groups exhibited significantly elevated levels of both IL-4 and TNF-α (p < 0.05; Figures 6, 7 and 8). Notably, IL-4 expression was significantly elevated, whereas TNF-α expression was significantly downregulated in the PD-, allopurinol-, and DB-treated groups compared with the AIN group (p < 0.05; Figures 6, 7 and 8). The results indicate that PD downregulated the adenine-induced inflammatory response in the kidneys. The inflammatory factors of immunohistochemistry stain (original magnification, 100×). The IL-4, TNF-α, Bcl-2, CASP3, and TGF-β1 in the normal group (A, B, C, D, and E); the IL-4, TNF-α, Bcl-2, CASP3, and TGF-β1 in the AIN group (F, G, H, I, and J); the IL-4, TNF-α, Bcl-2, CASP3, and TGF-β1 in the PD treatment group (K, L, M, N, and O); the IL-4, TNF-α, Bcl-2, CASP3, and TGF-β1 in the allopurinol treatment group (P, Q, R, S, and T); the IL-4, TNF-α, Bcl-2, CASP3, and TGF-β1 in in the DB treatment group (U, V, W, X, and Y). In the figure, the area presented in tan color is positive for immunohistochemical staining. IL-4: interleukin 4; TNF-α: tumor necrosis factor α; Bcl-2: B-cell CLL/lymphoma 2; CASP3: caspase 3; TGF-β1: transforming growth factor β1; AIN: adenine-induced nephropathy; PD: polydatin; DB: desuric benzbromarone. The analysis of immunohistochemistry stain by the integral optical density (IOD). The data are presented as means ± standard deviation (SD). *p < 0.05 vs. normal group, #p < 0.05 vs. AIN group. IL-4: interleukin 4; TNF-α: tumor necrosis factor α; Bcl-2: B-cell CLL/lymphoma 2; CASP3: caspase 3; TGF-β1: transforming growth factor β1. AIN: adenine-induced nephropathy; PD: polydatin; DB: desuric benzbromarone. The analysis of mRNA relative expression. The data are presented as means ± standard deviation (SD). *p < 0.05 vs. normal group, #p < 0.05 vs. AIN group. IL-4: interleukin 4; TNF-α: tumor necrosis factor α; Bcl-2: B-cell CLL/lymphoma 2; CASP3: caspase 3; TGF-β1: transforming growth factor β1; AIN: adenine-induced nephropathy; PD: polydatin; DB: desuric benzbromarone. PD inhibits apoptosis after renal injury To examine the effect of PD on apoptosis in AIN, we measured the expression levels of key apoptosis-related proteins, specifically the anti-apoptotic marker Bcl-2 and the pro-apoptotic effector CASP3. Immunohistochemical staining revealed that, compared with the normal group, the AIN group exhibited elevated CASP3 expression and significantly suppressed Bcl-2 expression (p < 0.05; Figures 6, 7). By contrast, the expression of CASP3 was inhibited and the expression of Bcl-2 was upregulated in the PD, allopurinol and DB treatment groups compared with the AIN group (p < 0.05; Figures 6 and 7). The relative abundance of CASP3 mRNA showed a notable increase in the AIN group, while there was a significant reduction in the PD, allopurinol and DB treatment groups compared with the AIN group (p < 0.05; Figure 8). We observed a significant reduction in relative Bcl-2 mRNA expression in renal tissues from the AIN group. However, the PD, allopurinol, and DB treatment groups showed an upregulated trend compared with the AIN group (p < 0.05; Figure 8). These findings demonstrate that PD suppresses apoptosis, thereby contributing to its renoprotective effect against AIN. PD reduces fibrosis after renal injury Masson’s trichrome staining showed the fibrosis situation of the kidneys of mice in different groups of our experimental group (Figure 9). The degree of fibrosis in the AIN group is relatively high. The degree of fibrosis in the PD treatment group, allopurinol treatment group, and DB treatment group is similar, but not as severe as that in the model group. TGF-β1 is a key cytokine that promotes renal tubulointerstitial fibrosis by stimulating myofibroblasts and increasing the expression of extracellular matrix. The present study detected the expression of TGF-β1 by immunohistochemistry (Figures 6 and 7) and RT-qPCR (p < 0.05; Figure 8). The results of both experiments demonstrated a notable increase in the AIN group when contrasted with the normal group, while a marked reduction was observed in the PD-, allopurinol- and DB-treated groups. These results indicated that PD treatment can also reduce the expression of TGF-β1, reduce the degree of fibrosis and further protect renal function. The Masson-stains of renal tissue (original magnification, 200×). The renal cortex of normal group (A), AIN group (C), PD treatment group (E), allopurinol treatment group (G), and DB treatment group (I); and the renal medulla of normal group (B), AIN group (D), PD treatment group (F), allopurinol treatment group (H) and DB treatment group (J). Masson staining showing the fibrosis situation of the kidneys of mice in different groups of our experimental group. The blue is where the fibers are stained. The degree of fibrosis in the AIN group (C, D) is relatively high. The degree of fibrosis in the PD treatment group (E, F), allopurinol treatment group (G, H), and DB treatment group (I, J) is similar, but it is not as severe as that in the model group. AIN: adenine-induced nephropathy; PD: polydatin; DB: desuric benzbromarone. PD can effectively improve the recovery rate To determine whether PD enhances recovery from AIN, we calculated a recovery rate based on the integrated pathological parameters described above (urinary mAlb, BUN, SCr, SUA, UUA, LDH, SOD, injury scores, immunohistochemistry, and mRNA relative expressions) (Table 3). For each parameter, the recovery rate was calculated as (Treatment group mean − AIN group mean)/(Normal group mean − AIN group mean) × 100%, representing the mean percentage recovery from the disease state (AIN group) toward the physiological baseline (normal group). This metric reflects the extent to which pathological indicators are restored from the diseased state toward the physiological baseline (Normal group), expressed as a percentage. As shown in Table 3, PD significantly improved the overall recovery rate compared with other interventions, further substantiating its broad-spectrum renoprotective efficacy. Table 3.The recovery rates of analytical indicators.GroupBiomarkerAIN + PDAIN + allopurinolAIN + BDUrinary mAlb41.9641.9638.14BUN59.3452.3958.09SCr58.1053.6459.17SUA50.4352.2154.63UUA67.1760.2564.54LDH53.2240.3161.47SOD53.8347.0553.94Injury scores35.0030.0035.00ImmunohistochemistryIL-464.9475.0987.28TNF-α72.3366.9265.57Bcl-2244.07277.96341.37CASP370.0674.4799.21TGF-β157.8666.9348.02mRNA relative expressionIL-4156.11163.62206.43TNF-α65.6563.7652.94Bcl-222.5124.2916.31CASP371.9053.4864.64TGF-β154.2952.7468.57Note. AIN: adenine-induced nephropathy; PD: polydatin; DB: desuric benzbromarone; mAlb: microalbuminuria; BUN: serum blood urea nitrogen; Scr: serum creatinine concentration; SUA: serum uric acid; UUA: urine uric acid; LDH: lactate dehydrogenase; SOD: superoxide dismutase; IL-4: interleukin 4; TNF-α: tumor necrosis factor α; Bcl-2: B-cell CLL/lymphoma 2; CASP3: caspase 3; TGF-β1: transforming growth factor β1. The recovery rates of analytical indicators. Note. AIN: adenine-induced nephropathy; PD: polydatin; DB: desuric benzbromarone; mAlb: microalbuminuria; BUN: serum blood urea nitrogen; Scr: serum creatinine concentration; SUA: serum uric acid; UUA: urine uric acid; LDH: lactate dehydrogenase; SOD: superoxide dismutase; IL-4: interleukin 4; TNF-α: tumor necrosis factor α; Bcl-2: B-cell CLL/lymphoma 2; CASP3: caspase 3; TGF-β1: transforming growth factor β1. Discussion Establishment of an AIN mouse model and its translational relevance In the present study, we successfully established a mouse model of AIN to evaluate the renoprotective effects of PD. Model validity was corroborated by pronounced renal histopathological lesions, elevated urinary mAlb, and increased serum levels of BUN and Scr, these findings that are fully consistent with the characteristic phenotypic features of AIN [38–40]. The selection of ICR mice was a deliberate and scientifically justified strategy to maximize the translational relevance of our results. First, ICR mice exhibit stable metabolic phenotypes and highly reproducible AIN pathogenesis [39,41]. Notably, adenine metabolism in ICR mice closely mirrors the human pathway: excess dietary adenine is hepatically converted to 2,8-dihydroxyadenine (DHA), which precipitates in renal tubular tubes, leading to tubular obstruction, inflammatory cell infiltration, and progressive interstitial fibrosis, pathological hallmarks that faithfully recapitulate clinical AIN [42–44]. Second, baseline SUA concentrations in ICR mice (approximately 100–150 μmol/L) fall within a range more physiologically comparable to that observed in healthy humans than in many inbred strains. Moreover, key uric acid transporters (URAT1, GLUT9) are functionally conserved with their human orthologs [6,45,46]. Third, as an outbred strain, ICR mice offer an optimal compromise between genetic heterogeneity and experimental reproducibility, thereby better reflecting the genetic diversity inherent to human populations [47,48]. Finally, the model robustly reproduces core pathological features of human AIN, including hyperuricemia, proximal tubular injury, interstitial fibrosis, and oxidative stress, further reinforcing its clinical translatability [49,50]. To further validate the translational relevance of this model, we benchmarked SUA and UUA levels against the clinical diagnostic criterion for human hyperuricemia (fasting SUA > 420 μmol/L) [51]. Adenine administration induced a significant elevation in SUA, accompanied by increased UUA excretion, reflecting both impaired renal uric acid clearance and compensatory urinary excretion. This dual pathophysiological alteration faithfully recapitulates the hallmark features of human hyperuricemic nephropathy. Although absolute SUA concentrations in mice are not directly translatable to human values, the magnitude of SUA elevation, which is relative to species-specific physiological baselines, was sufficient to elicit renal pathological changes that closely recapitulate those observed in human hyperuricemic nephropathy [52]. Concurrently, the increase in UUA mirrors the early clinical phase of human disease, characterized by transient hyperuricosuria preceding progressive renal dysfunction [53]. Thus, the translational value of this model lies not in numerical equivalence of SUA levels, but in its faithful recapitulation of the pathological cascade from uric acid dysregulation to structural renal damage. This positions the model as a robust preclinical platform for mechanistic studies of early-stage hyperuricemic nephropathy and for the evaluation of urate-lowering therapeutic interventions. Experimental design robustness and control of variability To ensure the reliability and scientific rigor of this study, we implemented multiple strategies to mitigate potential confounding factors. Randomization was performed using a computer-generated number table to assign mice to experimental groups. This approach guaranteed a balanced distribution of baseline characteristics and minimized potential confounding from inter-individual variability [54]. Standardized environmental conditions and operational procedures were strictly maintained throughout the experiment, and all interventions were performed by the same trained researchers following established, validated protocols [55]. Importantly, baseline characteristics, including body weight, SUA, and renal function parameters, were comparable among groups prior to intervention (p > 0.05), effectively minimizing baseline bias. Based on preliminary experiments and prior literature, the sample size (n = 10 per group) was determined through power analysis, employing an effect size of 0.8, a significance level of α = 0.05, and a statistical power of 1−β = 0.9 [56]. Subsequent post hoc analysis confirmed that the study was adequately powered to detect significant differences in core efficacy indicators. During statistical analysis, outliers were rigorously identified using Grubbs’ test (α = 0.05); only a minimal number of data points from secondary outcome measures were excluded [57]. This conservative approach preserved robust intra-group consistency while ensuring statistically significant inter-group differences for all primary outcomes. The adenine dosing regimen (0.1%, administered three times daily) was selected based on established dose-optimization principles. Previous studies have reported that 0.3% dietary adenine leads to high mortality within 3–4 days, whereas 0.2% adenine induces stable chronic renal failure with acceptable survival rates [58]. Accordingly, the 0.1% dose employed in this study represents a further refined regimen, balancing safety, efficacy, and tolerability. Moreover, the thrice-daily administration schedule was adopted to mitigate fluctuations in systemic adenine exposure, which arises from its inherently low aqueous solubility [36]. To minimize survival bias, we implemented a standardized animal replacement protocol: any mice that died during the study were promptly replaced with age-, body weight–, and baseline physiological parameter–matched ICR mice. To evaluate the potential influence of this replacement strategy on our primary outcomes, we conducted two-dimensional stratified analyses of core renal function endpoints (BUN and Scr) comparing results from (i) the full dataset (original mice plus replacements) and (ii) the subset comprising only original mice that survived to study completion. No statistically significant differences in treatment effect sizes were observed between these two analytical approaches (p > 0.05), confirming that survival bias did not meaningfully affect our conclusions. We acknowledge, however, that post‑mortem pathological examinations were not performed on mice that died during the experiment; this limitation will be addressed in future studies. PD attenuates renal dysfunction in AIN Scr and BUN are widely accepted clinical biomarkers for assessing renal function [59,60], while urinary mAlb serves as a sensitive supplementary indicator of early glomerular or tubular injury [61,62]. Under physiological conditions, the glomerular basement membrane (GBM) acts as a size- and charge-selective barrier that effectively restricts albumin filtration. However, adenine-induced GBM damage and/or impaired proximal tubular reabsorption disrupt this barrier function, resulting in increased urinary albumin excretion [59,62]. In the present study, Scr, BUN, and urinary mAlb levels were significantly elevated in the AIN model group relative to the normal control group (p < 0.05). Notably, treatment with PD, allopurinol, or DB markedly attenuated these pathological increases, suggesting that PD ameliorates renal dysfunction in AIN. Furthermore, analysis of the UUA/mAlb and SUA/mAlb ratios provided additional mechanistic insight into the interplay between uric acid handling and renal injury. Both ratios were significantly reduced in the AIN group, consistent with impaired tubular uric acid excretion and progressive structural and functional renal damage, which are hallmarks of CKD. Among the treatment groups, distinct patterns emerged: PD partially restored both UUA/mAlb and SUA/mAlb ratios, suggesting preservation of residual renal function, which are likely mediated by its anti-inflammatory and anti-fibrotic properties. Allopurinol produced a more pronounced improvement in the UUA/mAlb ratio, consistent with its primary mechanism of action, that is inhibition of xanthine oxidase and consequent reduction in uric acid synthesis. By contrast, DB showed the lowest UUA/mAlb and SUA/mAlb ratios across all treatment groups, as its uricosuric mechanism is compromised in the context of AIN, which is dependent on functional proximal tubules. Collectively, these ratio-based analyses underscore the potential therapeutic advantages of PD and allopurinol in the management of AIN. PD alleviates oxidative stress in renal tissue in AIN Accumulating evidence indicates that oxidative stress is a pivotal pathogenic mechanism in AIN, characterized by excessive generation of ROS, intracellular calcium overload, and dysregulation of energy metabolism [63]. ROS exacerbate renal injury through multiple pathways, including induction of lipid peroxidation, disruption of cellular and organellar membrane integrity, and consequent impairment of renal tissue architecture and function [64–66]. Consistently, oxidative stress has been demonstrated to participate in the progression of AIN, accompanied by accumulation of LDH and other peroxidation products [64]. SOD, a critical endogenous antioxidant enzyme responsible for scavenging superoxide radicals, serves as a key indicator of the kidney’s capacity to counteract oxidative damage [67]. In the present study, AIN induction markedly suppressed SOD activity while significantly elevating LDH activity in renal tissue, findings indicative of profound oxidative stress [68]. Remarkably, treatment with PD, allopurinol, or DB effectively reversed these alterations: all three agents significantly restored SOD activity and reduced LDH activity relative to the untreated AIN group. Collectively, these results demonstrate that PD mitigates oxidative stress in the kidneys during AIN, thereby contributing mechanistically to its renoprotective effects. PD modulates inflammatory responses in AIN Inflammatory activation and dysregulated cytokine expression represent central pathological features of AIN [69]. Although inflammatory cytokines initially mediate protective immune defense, excessive and sustained inflammation exacerbates renal injury through ROS generation and infiltration of inflammatory cells [69]. In the present study, immunohistochemistry and RT-qPCR revealed that the AIN group exhibited significantly elevated levels of both the pro-inflammatory cytokine TNF-α and the anti-inflammatory cytokine IL-4 compared with the normal group (p < 0.05). Notably, treatment with PD, allopurinol, or DB significantly increased IL-4 expression and decreased TNF-α expression relative to the untreated AIN group (p < 0.05). These findings indicate that PD attenuates renal inflammation in AIN by restoring the balance between pro- and anti-inflammatory mediators [70,71]. PD inhibits renal cell apoptosis in AIN Apoptosis is a pivotal pathogenic mechanism underlying the progression of AIN [72,73]. Bcl-2, a central anti-apoptotic regulator, promotes cell survival by suppressing the intrinsic apoptotic cascade [74]. In the context of AIN, upregulated Bcl-2 protects renal cells from urate crystal-induced apoptosis and preserves structural and functional integrity. In contrast, CASP3, a key effector protease in the apoptotic pathway, mediates irreversible cellular dismantling upon activation and thus contributes significantly to renal parenchymal injury [75]. Consequently, pharmacological inhibition of CASP3 activity represents a promising therapeutic strategy for mitigating AIN progression. Immunohistochemical analysis revealed that, relative to the normal control group, the AIN model group exhibited significantly elevated CASP3 expression and markedly reduced Bcl-2 expression in renal tissue (p < 0.05). In marked contrast, treatment with PD, allopurinol, or DB significantly reversed these alterations, downregulating CASP3 and upregulating Bcl-2 (p < 0.05). These immunohistochemical findings were further validated at the transcriptional level by RT-qPCR, which demonstrated corresponding changes in Bcl-2 and CASP3 mRNA expression. Collectively, these data demonstrate that PD attenuates renal tubular cell apoptosis in AIN, thereby reinforcing its renoprotective properties. The protective mechanism of PD glycoside against AIN Although this study did not directly validate specific molecular signaling pathways, the observed amelioration of inflammation, apoptosis, and fibrosis aligns closely with the well-documented pharmacological properties of PD. A substantial body of prior evidence demonstrates that PD possesses potent antioxidants, anti-inflammatory, immunomodulatory, and cytoprotective activities [25,76–78]. Notably, PD has been shown to confer protection against various tissue injuries, including cardiovascular diseases, arthritis, and inflammatory damage [25,78]. Moreover, it can inhibit platelet aggregation, regulate lipid metabolism, counteract lipid peroxidation, and exert antishock effects [79–81]. Regarding signaling pathways implicated in AIN, accumulating evidence indicates that PD exerts renoprotective effects via coordinated modulation of multiple keys signaling cascades. Specifically, PD has been shown to inhibit NF-κB activation by suppressing p65 phosphorylation, nuclear translocation, and IκBα degradation [67,68], which finds consistent with our observation that PD significantly reduced renal TNF-α levels and attenuated tubulointerstitial inflammation. Moreover, PD modulates the Bax/Bcl-2 ratio and downregulates cleaved CASP3 expression in experimental models of renal injury [69,70], providing a molecular basis for our observation of reduced tubular epithelial cell apoptosis following PD treatment. In addition, PD suppresses the TGF-β/Smad fibrotic pathway by inhibiting TGF-β1 expression and Smad2/3 phosphorylation, thereby diminishing α-SMA–positive myofibroblast accumulation and extracellular matrix deposition [71,72] a mechanism that aligns with our histological and biochemical data showing decreased renal collagen deposition and fibrosis. Collectively, these mechanistic insights support a multifaceted renoprotective role for PD in AIN, mediated through concurrent suppression of inflammatory, apoptotic, and fibrotic pathways. It is important to acknowledge that these mechanistic interpretations are inferred from the existing literature rather than derived from direct experimental evidence obtained in this study. Therefore, future studies employing Western blot analysis are warranted to verify the regulation of NF-κB, apoptosis, and TGF-β/Smad pathways and to establish direct causal relationships between these pathways and the renoprotective effects of PD in AIN. Comparative analysis of PD with standard clinical drugs Allopurinol and DB are the first-line clinical urate-lowering agents with well-established efficacy, however they exhibit potential adverse effects. Comparison with these drugs provides a valuable context for evaluating the clinical value and safety profile of PD. Allopurinol, a prototypical xanthine oxidase inhibitor, lowers SUA levels by suppressing its de novo synthesis and remains a cornerstone in the pharmacologic management of gout [82]. Although generally well tolerated at therapeutic doses, allopurinol exhibits low lipid solubility, resulting in predominantly renal excretion of its metabolites [83,84]. Consequently, in patients with impaired renal function, allopurinol use is associated with an elevated risk of progressive nephrotoxicity and severe cutaneous adverse reactions, particularly in genetically susceptible individuals such as Stevens–Johnson syndrome [85,86]. Mechanistically, allopurinol acts upstream by inhibiting uric acid production, thereby indirectly mitigating urate-induced inflammation and oxidative stress. However, its direct effects on renal tubular cell apoptosis and established interstitial fibrosis remain limited, as it does not robustly modulate key profibrotic signaling pathways, most notably the TGF-β/Smad axis [87,88]. Consequently, while allopurinol effectively lowers systemic uric acid levels, its capacity to ameliorate structural renal damage in AIN is restricted. This functional–structural dissociation was evident in our outcomes. Allopurinol produced a more pronounced improvement in the UUA/mAlb but conferred only modest benefit with respect to histopathological and biomarker indicators of structural renal damage. DB is a benzofuran-derived uricosuric agent that selectively inhibits URAT1, thereby suppressing renal uric acid reabsorption and enhancing urinary uric acid excretion [6,89]. It remains effective in some patients with advanced renal impairment [18,90]. However, rare but severe fulminant hepatic necrosis has been reported in Caucasians, leading to its classification as a second-line agent in some Western guidelines, whereas it is still widely used clinically in China [91]. Mechanistically, DB acts downstream by enhancing uric acid excretion. However, its efficacy is markedly attenuated in advanced CKD due to extensive tubular atrophy and interstitial fibrosis [92]. Moreover, pharmacologically induced uricosuria may elevate intratubular pressure and exacerbate oxidative stress, potentially triggering tubular epithelial apoptosis and thereby limiting its renoprotective potential [90,93]. Consistent with this mechanism-dependent constraint, DB yielded the lowest UUA/mAlb and SUA/mAlb ratios among all treatment groups [94]. This pattern underscores DB’s dependence on preserved tubular integrity, that a condition profoundly compromised in AIN. In contrast, PD exhibits multitarget pharmacological effects that directly counteract the core pathological processes of AIN [76]. Specifically, it not only lowers SUA levels but also suppresses inflammasome activation and the subsequent release of pro-inflammatory cytokines, scavenges ROS, enhances endogenous antioxidant capacity, inhibits tubular epithelial cell apoptosis via modulation of the Bcl-2/Bax ratio and CASP3 cleavage, and blocks TGF-β/Smad signaling to attenuate extracellular matrix deposition and interstitial fibrosis [95–98]. By concurrently targeting inflammation, oxidative stress, apoptosis, and fibrosis PD effectively disrupts the self-perpetuating pathogenic cascade that accelerates CKD development in AIN. These mechanistic advantages were corroborated by our functional outcomes that PD restored both the UUA/mAlb and SUA/mAlb ratios, reflecting preserved residual renal function and reduced structural renal injury. Collectively, these findings indicate that PD’s therapeutic advantage stems not merely from urate-lowering effects, but rather from its ability to concurrently modulate multiple pathogenic pathways. Although allopurinol exerts benefit primarily by inhibiting uric acid production and DB by promoting renal urate excretion, their utility in AIN is limited. In contrast, PD simultaneously targets key pathological processes, thereby offering a more holistic and sustainable therapeutic strategy for the long-term management of AIN. Clinical translation potential and future directions of PD As a naturally occurring small-molecule compound, PD demonstrated significant renoprotective effects in this study, effectively ameliorating adenine-induced renal dysfunction and associated histopathological injury. Compared with the conventional uricosuric agent DB and the xanthine oxidase inhibitor allopurinol, PD exhibits a more favorable safety and tolerability profile, with fewer clinically reported adverse effects [27,76,79]. The administered dose (15 mg/100 g body weight, intragastrically) was optimized based on preliminary dose-ranging studies. A dose of 10 mg/100 g elicited only moderate effects; 15 mg/100 g conferred robust renoprotection without evident hepatorenal toxicity; and 20 mg/100 g resulted in mild elevation of hepatic enzymes [79]. Despite its promising therapeutic efficacy, several challenges must be addressed to enable successful clinical translation. Pharmacokinetically, PD exhibits an oral bioavailability of approximately 42% in rodents and a plasma half-life of 4.2 ± 0.5 h in mice [76,79], however, it undergoes rapid hepatic glucuronidation, thereby limiting systemic exposure and shortening its duration of action [26]. Consequently, future efforts should focus on optimizing the pharmacokinetic profile of PD through approaches such as designing prodrugs or cyclodextrin inclusion complexes to mitigate first-pass metabolism, developing sustained-release or nanocarrier-based delivery systems to enhance oral bioavailability, and performing dedicated clinical pharmacokinetic studies to guide dose selection and adjustment in special populations. Formulation challenges also arise from PD’s poor water solubility (0.05 mg/mL at 25 °C) [26]. Promising approaches to overcome this limitation include lipid‑based nanosuspensions or micellar formulations to improve solubility and absorption, renal‑targeted delivery systems (e.g., ligand‑modified liposomes or nanoparticles) to enhance renal accumulation, and solid dispersion technology to improve dissolution rate and oral bioavailability [28]. Regarding safety, long-term rodent toxicity studies indicate a favorable safety margin for PD, with no overt toxic effects observed at doses up to fivefold the therapeutic dose [99,100]. Nevertheless, further large-scale clinical investigations are warranted to determine the long-term safety profile of PD in humans and to assess its potential drug interactions, assess potential drug–drug interactions, and establish appropriate dosage ranges for vulnerable populations, such as pregnant women and the elderly. Future studies should validate the renoprotective effects of PD in more clinically relevant models. Uricase-knockout (Uox−/−) mice, lacking functional uricase and thereby recapitulating human uricase deficiency, exhibiting SUA concentrations within the physiological human range and developing renal injury predominantly through chronic hyperuricemia rather than direct chemical toxicity. This feature renders the Uox−/− model especially well-suited for mechanistic dissection of hyperuricemia-driven nephropathy [101–103]. Transgenic models targeting key urate transporters (such as URAT1 overexpression or ABCG2 knockout) could further clarify whether PD exerts its effects by modulating renal uric acid handling. Moreover, integrative models incorporating additional comorbid risk factors. For instance, Uox−/− mice fed a high-fructose diet or crossed onto diabetic backgrounds, which would more faithfully mirror the multifactorial pathogenesis of human CKD, thereby enabling robust assessment of PD’s therapeutic efficacy in high-risk populations [101,102,104]. The limitations of this study This study has several limitations that should be acknowledged. First, the proposed involvement of the NF-κB, Bax/Bcl-2, and TGF-β/Smad signaling pathways is based on inferences drawn from the existing literature rather than direct experimental validation within this study. Future work employing specific antibodies, pathway inhibitors, or genetic knockdown will be essential to confirm the modulation of these pathways. Second, postmortem pathological examinations were not performed on mice that died during the experiment, limiting definitive analysis of causes of death. Third, although the sample size was statistically adequate to detect the observed effects, expanding the cohort size in future studies could further strengthen the statistical power and generalizability of the findings. Conclusions In the present study, we established a murine model of AIN to investigate the renoprotective effects of PD and elucidate the underlying molecular mechanisms. Adenine-induced renal impairment led to significant functional and histopathological abnormalities, all of which were markedly attenuated by PD treatment. Notably, PD preserved both the structural integrity and functional competence of renal tubules and glomeruli. Comprehensive mechanistic analyses revealed that PD exerts its therapeutic effects through multiple coordinated pathways, including modulation of immune-inflammatory responses, suppression of apoptosis, and inhibition of fibrotic progression. These findings provide a robust experimental foundation and theoretical rationale for the potential clinical application of PD in uric acid-induced renal injury. However, further mechanistic validation and well-designed clinical trials are warranted to advance its translational development.